Ozempic/Wegovy : Approximately 50% more effective than semaglutide-based alternatives Real-world data : Patients on Mounjaro are 3 times more likely to achieve 15% body weight loss compared to semaglutide users Dual-Action Mechanism Unlike single-action medications (Ozempic/Wegovy), Mounjaro works on both GLP-1 and GIP receptors , providing: Enhanced appetite suppression Improved blood sugar control Better insulin sensitivity Sustained weight loss maintenance Diabetes Management For type 2 diabetes patients, Mounjaro: Effectively lowers blood glucose levels Reduces insulin requirements in combination therapy Improves cardiovascular outcomes Supports long-term metabolic health Side Effects and Safety Considerations Common Side Effects Most Canadians tolerate Mounjaro well, with side effects typically subsiding within 24 weeks: Nausea (most common, usually temporary) Diarrhea or constipation Vomiting Reduced appetite Indigestion Management Tips : Taking Mounjaro with food, staying hydrated, and gradual dose escalation minimize gastrointestinal discomfort
Chang C.H., Tsai W.C., Lin M.S., Hsu Y.H., Pang J.H
Currently, there is insufficient high-quality clinical evidence to support its use for IBS symptom management
Wegovy, semaglutide 2.4mg is a prescription medication used for treatment of obesity
With powerful antioxidants and calming botanicals, it delivers a radiant glow and refreshed complexion in just one use
Recommendations and Guidelines Maximize the benefits of Mounjaro by following these recommendations and guidelines: Inject Mounjaro once a week, at any time of day
